肿瘤-睾丸抗原MAGE-A1、MAGE-A3、MAGE-A4在胰腺癌中的表达及意义

Expression and Biological Significance of Tumor-Testis Antigens MAGE-A1,MAGE-A3,and MAGE-A4 in Pancreatic Cancer

目的:检测肿瘤-睾丸抗原(CTA)黑色素抗原A(Melanoma Antigen-A,MAGE-A)在胰腺癌中的表达情况,寻找胰腺癌中高表达MAGE亚型。方法:应用逆转录聚合酶链反应(RT-PCR)方法对52例胰腺癌组织及癌旁正常组织中MAGE亚型MAGE-A1、MAGE-A3、MAGE-A4的表达情况进行检测。结果:癌旁正常组织中无MAGE亚型的表达,MAGE-A1、MAGE-A3、MAGE-A4在52例胰腺癌的阳性表达率分别为5.77%(3/52)、44.23%(23/52)、23.08%(12/52);经相关分析,MAGE-A1、MAGE-A4的阳性表达与患者的年龄、性别、病变部位、分化程度无明显相关关系(P>0.05);MAGE-A3的阳性表达与肿瘤的分化程度呈负相关(r=-0.294,P=0.034),而与患者的年龄、性别、病变部位无明显相关关系(P>0.05)。结论:胰腺癌中MAGE亚型中MAGE-A3表达率最高,其阳性表达与肿瘤的分级呈负相关关系;MAGE-A3有望成为胰腺癌免疫治疗特异性的靶点。

Objective： The present work aims to explore the expression and biological specificity of cancer-testis antigens andmelanoma antigen-A （MAGE-A） in pancreatic carcinoma, which might provide the theoretical and experimental foundation for the immtmotherapy of pancreatic cancer. Methods： Paraffin-embedded tissue specimens of 52 cases with pancreatic carcinoma were selected. Expression levels of MAGE-A1, MAGE-A3, and MAGE-A4 in the 52 tissue specimens were determined and analyzed by reverse transcription polymerase chain reaction. Results： Antigens MAGE-A1, MAGE-A3, and MAGE-A4 were not expressed in the normal paraneoplastic pancreatic tissues. The positive expression rates of MAGE-A1, MAGE-A3, and MAGE-A4 in the 52 pancreatic cancer cases were 5.77% （ 3/52 ）, 44.23% （ 23/52 ）, and 23.08% （ 12/52 ）, respectively. No significant correlation between the positive expression levels of MAGE-A1 and MAGE-A4 and factors such as age and gender Of the patient, cancer site, and pathological grading of the tu- mor was found in the 52 cases with pancreatic cancer （ P 〉 0.05 ）. MAGE-A3 expression is negatively correlated with pathological grades of the tumor （ r = -0.294, P = 0.034 ）. Conclusion： MAGE-A3 is the most commonly expressed antigen in pancreatic cancer among the three subtypes of MAGE. There is a negative correlation between the high expression of MAGE-A3 and pathological grade of tumor in pancreatic cancer. MAGE-A3 might be a potentially promising target for antigen-specific immunotherapy of pancreatic cancer.